Telix Pharmaceuticals
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$1.8M
Doctors Paid
2,939
Transactions
5,700
2024 Total
$857,108
Payment Breakdown by Category
Consulting$630,330 (36.0%)
Research$377,215 (21.5%)
Travel$258,381 (14.8%)
Food & Beverage$198,984 (11.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $630,330 | 207 | 36.0% |
| Unspecified | $377,215 | 50 | 21.5% |
| Travel and Lodging | $258,381 | 406 | 14.8% |
| Food and Beverage | $198,984 | 4,897 | 11.4% |
| Honoraria | $190,433 | 106 | 10.9% |
| Education | $52,598 | 25 | 3.0% |
| Grant | $43,296 | 8 | 2.5% |
| Gift | $36.96 | 1 | 0.0% |
Payments by Type
General
$1.4M
5,650 transactions
Research
$377,215
50 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 68Ga PSMA-11 PET in Patients with Prostate Cancer | $199,000 | 0 | 24 |
| Imaging TGF-beta in the tumour microenvironment | $48,533 | 0 | 3 |
| Evaluating activity of the TLX591 TGF-beta trap | $48,533 | 0 | 3 |
| potential clinical trial investigating PSMA in Radiation Therapy | $21,200 | 0 | 2 |
| 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT forDetection of Invasive Lobular Breast Cancer:Interim Report from an Exploratory Trial | $19,700 | 0 | 2 |
| Use of Illucix (68Ga PSMA-11) and uExplorer Total Body PET/CT Imaging | $14,100 | 0 | 3 |
| Product doses for IIT study: 68-Ga-PSMA-11 PET in Patients with Prostate Cancer | $12,200 | 0 | 4 |
| Pre-operative localization of parathyroid adenomas using GA-68 PSMA PET/CT | $6,200 | 0 | 4 |
| Product doses for IIT study: Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes\00A0 | $4,650 | 0 | 3 |
| Product doses for Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging | $3,100 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Jaideep Sohi, M.d, M.D | Nuclear Medicine | Chicago, IL | $440,702 | $0 |
| Dr. Amir Lavaf, M.d, M.D | Radiation Oncology | Palm Springs, CA | $59,322 | $0 |
| Dr. Brian Shuch, Md, MD | Urology | Los Angeles, CA | $51,281 | $0 |
| Umesh Oza, Md, MD | Diagnostic Radiology | Dallas, TX | $31,599 | $0 |
| Dr. Delphine Chen, Md, MD | Nuclear Medicine | Seattle, WA | $22,713 | $0 |
| Jeremie Calais, Md, MD | Nuclear Imaging & Therapy | Los Angeles, CA | $21,551 | $0 |
| Michael Veronesi, Md, MD | Student in an Organized Health Care Education/Training Program | Indianapolis, IN | $20,477 | $0 |
| Sanoj Punnen | Urology | Miami, FL | $18,753 | $0 |
| John De Groot, M.d, M.D | Neurology | Houston, TX | $17,226 | $0 |
| Pedro Barata, M.d, M.D | Hematology & Oncology | New Orleans, LA | $15,543 | $0 |
| Dr. Paul Yonover, Md, MD | Urology | Chicago, IL | $14,995 | $0 |
| Scott Tagawa, Md, MD | Hematology & Oncology | New York, NY | $14,841 | $0 |
| Dr. Phillip Kuo, M.d. Ph.d, M.D. PH.D | Nuclear Radiology | Duarte, CA | $13,410 | $0 |
| Dr. Munir Ghesani, M.d, M.D | Nuclear Medicine | Princeton, NJ | $12,026 | $0 |
| Dr. Marc Bjurlin, Do, DO | Urology | Kinston, NC | $11,962 | $0 |
| Dr. Derek Johnson, M.d, M.D | Neurology | Rochester, MN | $10,748 | $0 |
| Mark Tann, M.d, M.D | Nuclear Imaging & Therapy | Indianapolis, IN | $9,734 | $0 |
| Dr. Bradley Fehrenbach, Md, MD | Nuclear Medicine | Lakewood, CO | $9,653 | $0 |
| Dr. Priya Kumthekar, Md, MD | Neurology | Chicago, IL | $9,329 | $0 |
| Pedram Heidari, M.d, M.D | Diagnostic Radiology | Boston, MA | $8,591 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $8,403 | $0 |
| Dr. Naveen Kella, M.d, M.D | Urology | San Antonio, TX | $8,246 | $0 |
| Dr. Alton Sartor, M.d, M.D | Medical Oncology | Rochester, MN | $7,638 | $0 |
| Seyed Nabavizadeh, Md, MD | Diagnostic Radiology | Philadelphia, PA | $7,567 | $0 |
| Dr. Ephraim Parent, Md, MD | Nuclear Radiology | Jacksonville, FL | $7,453 | $0 |
About Telix Pharmaceuticals
Telix Pharmaceuticals has made $1.8M in payments to 2,939 healthcare providers, recorded across 5,700 transactions in the CMS Open Payments database. In 2024, the company paid $857,108. The top product by payment volume is ILLUCCIX ($1.6M).
Payments were distributed across 78 medical specialties. The top specialty by payment amount is Nuclear Medicine ($516,799 to 51 doctors).
Payment categories include: Food & Beverage ($198,984), Consulting ($630,330), Research ($377,215), Travel & Lodging ($258,381).
Telix Pharmaceuticals is associated with 1 products in the CMS Open Payments database.